PinnyPeptide

HEP-1 (Gepon) vs Vilon

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

HEP-1 (Gepon)

Immune

Russian-approved 14-amino-acid immunomodulator derived from the ezrin protein.

Peptide B

Vilon

Bioregulators

Khavinson Lys-Glu dipeptide — immunomodulator with documented life-extension activity in mice.

Typical vial

5 mg

Typical dose

1,000-10,000 mcg

Half-life

Variable per route

FDA status

Not FDA approved. Approved in Russia as Gepon.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

HEP-1 (Gepon) effects

  • Macrophage activation and cytokine modulation
  • Enhanced mucosal immune defense
  • Antiviral activity in HIV, herpes, hepatitis (Russian clinical use)
  • Anti-inflammatory effects in chronic infectious conditions
  • Restoration of immune function in immunocompromised patients

Vilon effects

  • Reported immunomodulatory effects
  • Life-extension and tumor-reduction in mouse studies (Khavinson group)
  • Possible telomere-related activity
  • Support of T-cell function in elderly populations
  • Modulation of immune gene expression

HEP-1 (Gepon) side effects

  • Generally well-tolerated in Russian clinical use
  • Mild local irritation with topical or intranasal use
  • Occasional headache
  • Rare allergic reactions
  • Long-term safety with chronic use not extensively studied outside Russia

Vilon side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Caution in active autoimmune disease

HEP-1 (Gepon) dosing ranges

HIV/AIDS adjunct (Russian clinical)

10 mg · Once daily, oral or rectal · Per clinical protocol

Recurrent herpes (Russian clinical)

2 mg · Topical 3-4 times daily · 7-14 days per outbreak

Mucosal immunity research

1-5 mg · Intranasal or oral · Per research protocol

Vilon dosing ranges

Immune support / anti-aging research

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full HEP-1 (Gepon) guide → Full Vilon guide →

HEP-1 (Gepon) vs Vilon — common questions

What is the difference between HEP-1 (Gepon) and Vilon?

HEP-1 (Gepon): Russian-approved 14-amino-acid immunomodulator derived from the ezrin protein. Typical dose 1,000-10,000 mcg. Vilon: Khavinson Lys-Glu dipeptide — immunomodulator with documented life-extension activity in mice. Typical dose 1,000-5,000 mcg. Both fall under the Immune and Bioregulators categories.

Can you stack HEP-1 (Gepon) and Vilon?

Stacking HEP-1 (Gepon) with Vilon is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, HEP-1 (Gepon) or Vilon?

HEP-1 (Gepon) is typically dosed: Once daily, oral or rectal for HIV/AIDS adjunct (Russian clinical); Topical 3-4 times daily for Recurrent herpes (Russian clinical); Intranasal or oral for Mucosal immunity research. Vilon is typically dosed: Once daily (SubQ) or sublingual for Immune support / anti-aging research.

Are HEP-1 (Gepon) and Vilon FDA approved?

HEP-1 (Gepon): Not FDA approved. Approved in Russia as Gepon. Vilon: Not FDA approved.

Related peptide comparisons

hep-1 vs thymalinhep-1 vs thymosin-alpha-1hep-1 vs vipbronchogen vs viloncardiogen vs viloncartalax vs vilon

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free